Drug Trial Radar · NCT06676579
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Jun 9, 2025
Primary completion
Mar 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
Conditions
- IgA Nephropathy (IgAN)
Interventions
AvacopanDrug
Avacopan is a complement 5a receptor (C5aR) antagonist, orally active.
PrednisoneDrug
0.4 mg/kg per day (maximum, 32 mg/day) for 2 months followed by dose tapering by 4 mg per day each month (total duration 6-9 months
Methylprednisolone (drug)Drug
Methylprednisolone 1g intravenous on day +1
PrednisoloneDrug
Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in proteinuria measured by results of protein total, 24-hour urine collection at baseline compared to collection at 12 months.Time frame: 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.